INSIGHTS ON UPSTREAM MANUFACTURING
-
De-Risking Cell Culture Media Scale-Up For Late-Stage Manufacturing
Explore practical approaches to scaling cell culture media manufacturing, from supply assurance to evolving quality requirements, digital formulation tools, and strategies for controlling costs.
-
Building A GMP-Ready Cell Line Development Strategy From Day One
Embedding manufacturing and regulatory readiness early streamlines development, reduces delays, and supports successful scale-up.
-
Accelerating A Promising Bispecific Antibody To The Clinic
See how an integrated perfusion and intensified fed-batch approach enabled rapid development of a sensitive protein process and successful clinical trial material production.
-
Intensification Of Upstream Operations With Dynamic Perfusion
Dynamic perfusion simplifies continuous cell culture by eliminating cell bleed. Compare upstream strategies across productivity to understand their potential for more efficient mAb production.
-
Saving Time And Money With Better Microbial Strain Selection9/2/2026
Deeper, automated E. coli screening can reduce cell line development costs by narrowing the design space, lowering the marginal cost of additional experiments, and improving downstream productivity through higher titers and cleaner harvests.
-
Analytical Blind Spots That Derail Microbial Programs Before The Clinic9/1/2026
High refolding yields aren’t enough. Learn how analytical characterization, structural equivalence testing, and optimized fermentation reduce scale-up risk and improve quality.
-
Single-Use Clarification Across Process Scales9/1/2026
Gain insight into how combining centrifugation with targeted depth and chromatographic clarification can reduce filter demand, ease facility constraints, and support efficient mAb harvest.
-
Optimizing mAb Production: Upstream Process Intensification Strategies9/1/2026
See how integrated upstream and downstream intensification strategies can increase monoclonal antibody yield, streamline workflows, improve facility utilization, and reduce manufacturing costs.
UPSTREAM MANUFACTURING SOLUTIONS
-
Rushing early development without planning for commercialization can lead to delays. Aligning process and analytical strategies from the start supports efficient scale-up and smoother manufacturing.
-
A stable producer cell line platform designed to replace transient transfection in AAV manufacturing, offering 10 to 15-fold titer improvements and simplified workflows from development through commercial scale.
-
Increase mAb output without adding capacity. See how intensified seed and production strategies can shorten timelines, reduce manual handling, lower facility burden, and improve productivity.
-
Build a more efficient path to clinical manufacturing with cGMP cell banks, scalable media, regulatory support, and flexible options designed to meet immediate development requirements.
-
When E. coli, CHO, and yeast fall short on titer, protein quality, or scalability, a P. fluorescens-based expression platform built on 25 years of strain engineering offers a different path.